Clinical trials: Trunk
Seborrheic Keratosis
An Open-Label Safety Study of A-101 Solution
This is an open-label safety study. During this study, the investigator will identify 4 eligible SK Target Lesions on each subject on the trunk, extremities and face.
- Trial name
- NCT02667288
- Testing
- A-101 Solution
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- Aclaris Therapeutics, Inc.
Cutaneous Squamous Cell Carcinoma
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to evaluate the efficacy of neoadjuvant cemiplimab as measured by Pathologic complete response (pCR) rate per independent central pathology review.
- Trial name
- NCT04154943
- Testing
- Cemiplimab
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic, Intractable Pain of the Trunk and/or Lower Limbs
Evaluating Anatomic Versus Targeted Lead Placement for Burst Stimulation Therapy During the Trial
Prospective, multi-center, randomized, single blind study
- Trial name
- DELIVERY (NCT03277378)
- Testing
- lead placement followed by BurstDR stimulation
- Where
- 25 sites in United States, Australia and 5 more
- Volunteers
- 270 people
- Sponsor
- Abbott Medical Devices
Chronic Pain
Evaluate St Jude Medical Prodigy Neuromodulation for FBSS or Chronic Pain of the Trunk and/or Limbs
The purpose of this study is to confirm long term efficacy and safety of the ProdigyTM neuromodulation system in the management of failed back surgery syndrome or chronic intractable pain of the trunk and/or limbs.
- Trial name
- Prodigy-I (NCT02143791)
- Testing
- Burst and Tonic stimulation
- Where
- 21 sites in Australia, Belgium and 7 more
- Volunteers
- 126 people
- Sponsor
- Abbott Medical Devices
Seborrheic Keratosis
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis
The primary objective of this study is to evaluate the safety and effectiveness of 2 concentrations of A-101 compared to Vehicle for the treatment of 4 seborrheic keratosis (SK) Target Lesions on the trunk, extremities and face.
- Trial name
- NCT03148691
- Testing
- A-101
- Where
- 9 sites in United States
- Volunteers
- 253 people
- Sponsor
- Aclaris Therapeutics, Inc.
Seborrheic Keratosis
A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
This is a randomized, double-blind, vehicle-controlled, parallel group study of A-101 Solution 40% compared with Vehicle Solution.
- Trial name
- NCT02667236
- Testing
- A-101 Solution, Vehicle Solution
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- Aclaris Therapeutics, Inc.